
Shares of pot company Curaleaf Holdings CURA.TO up 2.2% to C$1.17
Company, in partnership with Jupiter Research LLC, secures EU medical device certification for a handheld liquid inhalation device designed for medical cannabis administration
CURA says the device is certified as a Class IIa medical device
Company adds that the device includes a magnetic snap-in cartridge and a rechargeable power supply, engineered to provide a consistent and controlled cannabinoid delivery
"Achieving EU medical certification is more than a regulatory milestone — it's a signal that medical cannabis innovation is moving into the mainstream of global healthcare" - Curaleaf CEO Boris Jordan
Including session's moves, shares are down 48.21% YTD